LBBW Aktienanleihe MRK 22.11.2024/ DE000LB4PSA5 /
13/11/2024 17:15:11 | Var.-0.010 | Denaro13/11/2024 | Lettera13/11/2024 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
100.070EUR | -0.01% | - Quantità in denaro: - |
- Quantità in lettera: - |
MERCK KGAA O.N. | 125.00 EUR | 22/11/2024 | Call |
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA